ModerateAngiotensin-converting enzyme inhibitors (ACEi)×Proton pump inhibitors
Updated · Methodology
Mechanism
Enalapril is converted in the body to the active enalaprilat, with no other significant metabolism, and enalaprilat is excreted mainly by the kidneys (Renitec SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Cytochrome P450 enzymes in the liver metabolise omeprazole completely, mainly CYP2C19 and to a lesser extent CYP3A4. Omeprazole moderately inhibits CYP2C19, and its metabolites are excreted mainly in the urine (Losec SmPC, AEMPS). The enalapril documents describe neither a role for CYP2C19 nor absorption that depends on gastric acidity, and no document names this pair (Renitec and Losec SmPCs, AEMPS; Vasotec and Prilosec labels, US Food and Drug Administration, FDA). What they share are kidney warnings. Renal failure has been reported in some people taking enalapril, mainly those with severe heart failure or kidney disease. Acute tubulointerstitial nephritis, which can progress to renal failure, has been seen in people taking omeprazole (Renitec and Losec SmPCs, AEMPS).
Symptoms
The documents describe no symptoms specific to this combination. The shared concern is the kidneys. Enalapril can cause dizziness, cough and low blood pressure, including on standing. Angioedema of the face, lips, tongue or larynx can occur at any time during treatment (Renitec SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Omeprazole commonly causes headache, abdominal pain, constipation, diarrhoea, flatulence, nausea or vomiting (Losec SmPC, AEMPS). Acute tubulointerstitial nephritis with omeprazole can begin at any time during treatment and can progress to renal failure (Losec SmPC, AEMPS).
Management
The combination is not contraindicated, and the documents give no measures specific to this pair. The warnings for both drugs mention renal failure, however, so the combination requires caution (Renitec and Losec SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). In renal impairment, the starting dose of enalapril is set by creatinine clearance, and potassium and creatinine are monitored regularly (Renitec SmPC, AEMPS). In bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney, enalapril is started at low doses under close supervision, with monitoring of renal function (Renitec SmPC, AEMPS). If acute tubulointerstitial nephritis due to omeprazole is suspected, omeprazole is stopped and appropriate treatment is started promptly (Losec SmPC, AEMPS). The doses of enalapril and omeprazole are not changed because of the combination itself, as the documents describe no pharmacokinetic interaction between them (Renitec and Losec SmPCs, AEMPS; Vasotec and Prilosec labels, US Food and Drug Administration, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Prilosec (omeprazole) prescribing information (2024)– DailyMed setid b6761f84-53ac-4745-a8c8-1e5427d7e179, revisión 03/2024, secciones 4 y 7
- AEMPS: Ficha técnica: Enalapril (Renitec 20 mg) (nº registro 57773), secciones 4.4 y 4.5 (2022)– AEMPS, CIMA, nº registro 57773, revisión 01/2022, secciones 4.4 y 4.5
- FDA: Vasotec (enalapril maleate) prescribing information (2026)– FDA, DailyMed setid 39631f1f-5d19-43c1-b504-bf56d991ed97 (Bausch Health US), revised 01/2026, section PRECAUTIONS (Hyperkalemia; Drug Interactions)
- AEMPS: Ficha técnica: Omeprazol (Losec 20 mg) (nº registro 58377), secciones 4.4 y 4.5 (2026)– AEMPS, CIMA, nº registro 58377, revisión 06/2026, secciones 4.4 y 4.5